Nerve block injection during biopsy may slow prostate cancer
NCT ID NCT06703437
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 20 times
Summary
This early-phase trial tests whether injecting a long-acting nerve block (using dehydrated alcohol and lidocaine) around the prostate during a biopsy can slow cancer growth in 12 men with high-risk localized prostate cancer. The main goal is to check safety and find the best dose. Researchers believe blocking certain nerve signals may help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dehydrated alcohol (ethanol) and lidocaine
What this could lead to
If it works, this could point toward a way to slow prostate cancer progression by blocking nerve signals, potentially delaying or reducing the need for more aggressive treatments.
What could go wrong
This is a very early phase 1 trial with only 12 people, focused on safety and dosing. It is not designed to prove effectiveness, and the nerve block may not affect cancer outcomes. Risks include side effects from the alcohol injection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.